共 197 条
[1]
Trujillo JM(2021)GLP-1 receptor agonists: an updated review of head-to-head clinical studies Ther Adv Endocrinol Metab 12 2042018821997320-22
[2]
Nuffer W(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-30
[3]
Smith BA(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 121-39
[4]
Marso SP(2017)Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 377 1228-44
[5]
Daniels GH(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834-51
[6]
Brown-Frandsen K(2019)Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 381 841-62
[7]
Kristensen P(2021)Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Lancet Diabetes Endocrinol 9 653-323
[8]
Mann JF(2020)2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 41 255-e59
[9]
Nauck MA(2022)Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association Circulation 145 e722-66
[10]
Gerstein HC(2022)Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the american Diabetes Association (ADA) and the European Association for the study of diabetes (EASD) Diabetologia 65 1925-90